<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 199 patients were evaluated, which included 100 control patients (group 1), 91 HIV-positive patients who were receiving ARVT (group 2) and 8 patients without HIV treatment (group 3).</p>
